Haloperidol Pricing Options: Generic Haldol and Affordable Access to Antipsychotic Therapy

Haloperidol has been available as a generic medication for several decades following patent expiration. Generic oral tablets in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg strengths are available from multiple manufacturers, and the haloperidol decanoate long-acting injectable is also available generically. This extensive generic availability across formulations and strengths supports consistently low pricing for this antipsychotic. Retail cash prices for generic haloperidol oral tablets are low compared to second-generation atypical antipsychotics, many of which remain branded or entered the generic market more recently. A 30-day supply of haloperidol at typical therapeutic doses for schizophrenia or Tourette syndrome is often available for between five and twenty dollars at major retail pharmacies, with variation based on the dose and dispensing pharmacy. Prescription discount programs from free online coupon services provide access to pharmacy-negotiated pricing that can place haloperidol costs at the lower end of this range. For patients who are uninsured or who have high deductible plans, presenting a discount card at the pharmacy counter at the time of dispensing typically secures the lowest available price for generic haloperidol oral tablets. Haloperidol decanoate for long-acting injectable use is typically administered by a healthcare professional in a clinic or office setting, and pricing for the injectable formulation reflects both the product cost and the administration fee. Patients on long-acting injectable haloperidol should review their specific insurance coverage for both the medication and the clinical administration. Medicaid formularies include haloperidol oral tablets at the lowest cost tiers and haloperidol decanoate for patients who require the injectable formulation. Coverage of the long-acting injectable is particularly important for this population given the adherence challenges common in schizophrenia management. Medicare Part D plans cover generic haloperidol oral tablets at their lowest cost tiers. Patients who have been transitioned from costly second-generation antipsychotics to haloperidol when cost is a barrier should confirm that all relevant formulations and strengths are covered before assuming consistent access through their coverage plan. For patients who want to understand their cost options for antipsychotic therapy with haloperidol, exploring haldol-haloperidol pricing options helps identify the most accessible route to affordable treatment. For patients and families comparing antipsychotic options and their associated costs across the category, antipsychotic medication category patient guides provides useful comparative information.

Generic Pioglitazone: Consistency and Reliability After Patent Expiration

Pioglitazone transitioned from brand-exclusive availability to a competitive generic market following patent expiration. The branded product, Actos, served as the reference listed drug that generic manufacturers were required to demonstrate bioequivalence against before receiving FDA approval. Multiple manufacturers have now received this approval, and generic pioglitazone has been dispensed widely for years with a strong real-world record. FDA bioequivalence testing for pioglitazone requires manufacturers to demonstrate equivalent pharmacokinetic profiles, meaning the generic drug must reach the same blood concentration levels, at the same rate, as the brand reference. These parameters must fall within accepted bounds for the product to receive and maintain FDA approval. Pioglitazone's oral bioavailability and absorption characteristics make bioequivalence testing methodologically reliable for this drug class. Pioglitazone is available in 15 mg, 30 mg, and 45 mg tablet strengths. All three strengths have multiple FDA-approved generic versions. The breadth of generic availability across all strength options provides prescribers and patients with consistent access regardless of dose requirements. Tablet appearance differences between manufacturers are normal and expected in generic prescribing. Size, shape, coating color, and inactive ingredient choices differ across manufacturers because each produces their own tablet formulation consistent with their manufacturing capabilities. These visible differences do not reflect differences in the active drug delivered. Patients who notice a change in how their medication looks after a pharmacy fills the prescription from a new manufacturer may wonder whether they received the correct product. Asking the pharmacist to confirm the active ingredient and dose is a straightforward verification step that takes only a moment. The pharmacist can confirm that the product dispensed is an FDA-approved generic equivalent. Long-term blood glucose control on pioglitazone is monitored with hemoglobin A1C measurements approximately every three months until stable and at longer intervals once targets are achieved. If a patient's glucose control becomes less stable after a manufacturer switch, the change should be reported to their provider for clinical evaluation rather than assumed to be caused by the generic substitution without confirmation. The multi-manufacturer supply base for pioglitazone reduces the supply disruption risk that affects narrow-source generics. Patients on long-term type 2 diabetes management can generally expect consistent pioglitazone availability from their pharmacy. For patients who want to understand what generic availability means for their ongoing diabetes treatment, reviewing information about generic actos-pioglitazone reliability helps build informed long-term confidence in their prescription. For patients comparing diabetes medications and their generic equivalents, the resources at diabetes category medication guides provide useful comparative context.

Using Synthroid For Hypothyroidism: What Patients Should Know

Hypothyroidism is a condition that affects a significant number of people and can range from mild and occasional to persistent and severely disruptive. Understanding the available treatment options is an important part of managing symptoms effectively. Healthcare providers evaluate the severity of the condition and the patient's overall health profile before recommending a specific medication or combination of treatments. Allergic conditions affect hundreds of millions of people worldwide and range from mild seasonal symptoms to chronic conditions that persist throughout the year. The immune system's overreaction to harmless environmental substances such as pollen, dust mites, pet dander, and certain foods drives most allergic disease. Histamine, released by immune cells when they detect an allergen, is the primary chemical mediator responsible for the familiar symptoms of sneezing, runny nose, itchy eyes, and skin reactions. Synthroid (levothyroxine) belongs to the class of medications used for thyroid and is commonly considered by clinicians evaluating treatment options for this condition. Patients looking closely at synthroid for hypothyroidism will find that the medication offers a practical option for many individuals dealing with this specific issue, particularly when first-line approaches have provided incomplete relief. As with any prescription or over-the-counter medication, proper dosing and adherence to usage guidelines are essential to getting the most benefit from Synthroid while minimizing the risk of side effects. Taking the medication as directed, at the appropriate time of day, and for the full recommended duration helps ensure therapeutic blood levels are maintained. Patients should inform their healthcare provider of all other medications they are taking to check for potential interactions. For broader context on treatment options related to thyroid, https://mednewwsstoday.com/thyroid/ provides evidence-based information covering the full range of medications used in this therapeutic area, helping patients and caregivers compare approaches and make informed decisions alongside their medical team.

Teens and medicines that cause birth defects: Do doctors drop the ball?

By health.harvard.edu

My 14-year-old daughter recently started taking isotretinoin, a medication that can help severe acne — and that can cause severe birth defects. I knew that there was a process in place for preventing pregnancy in girls taking it, but I was caught off guard by just how many hoops we had to jump through to get her prescription.

There were two pregnancy tests a month apart at the beginning, continued monthly pregnancy tests as well as monthly online questions about contraception and her understanding of the effects of the medicine, and a special ID card that has to be brought to the pharmacy within a very short window after the monthly blood tests. I’d never seen anything like it, and I’m a doctor. It got me thinking: Why don’t we do this kind of thing for all the medications that cause birth defects? Are we dropping the ball?

The answer, says a recent study published in the journal Pediatrics, is yes.

For the study, researchers looked at 4,172 visits to a large Midwestern academic pediatric center. They found that 1,694 girls ages 14 to 25 got 4,506 prescriptions for Category D or X medications. Category D medications can cause birth defects, but in some cases the benefits outweigh the risks for a pregnant woman; for Category X medications, it’s felt that the risks outweigh the benefits.

There were all sorts of Category D and X medications prescribed, mostly by neurologists, dermatologists, and hematologist-oncologists. The five most common were topiramate, methotrexate, diazepam, isotretinoin, and enalapril. And here’s the scary part:

Less than a third of the girls got a prescription or referral for birth control, or even counseling about birth control.
Less than a quarter were asked questions about sexual activity.
Less than a sixth were asked questions about their period (like when they last got it).

What was particularly interesting was that when girls were in programs like the one my daughter is in, they got asked about sex and periods even less. That certainly is true for us: the dermatologist has yet to ask those questions of my daughter — or even to ask to meet with her alone, which is usually the best way to have a confidential conversation with a teen. I suppose she thinks that the monthly pregnancy test and online quiz is enough — but everybody knows how to lie on an online test, and the idea is to prevent the monthly pregnancy test from becoming positive, not just check to see if it is.

Nobody likes to think about their teen daughter having sex. In general, both parents and doctors do a not-so-great job of talking to girls about sexuality and contraception, despite the fact that by their senior year in high school, roughly two-thirds of U.S. teens have had sex. But what worries me is that many of the girls taking these medications might not fully understand the risks — or might have misconceptions about sex or birth control — and unwittingly cause harm to a baby.

Clearly, we doctors have got to get our act together. We need to be more conscientious, ask the awkward questions, offer the education and birth control. But parents can make a difference, too. Here’s what they can do:

Always ask about all the side effects of any medication your child is prescribed — including whether it causes birth defects.
Make sure your daughter has the facts when it comes to sex and birth control. Yes, it’s important to pass on your values — but be sure she has the information she needs. Whether she needs it at age 15 or 30, she still needs it. Do it on the early side. Better safe than sorry.
Encourage your daughter to meet alone, confidentially, with her health care providers. The most important thing isn’t that you know everything; the most important thing is that your daughter be safe and well.

Source: http://www.health.harvard.edu/blog/teens-and-medicines-that-cause-birth-defects-do-doctors-drop-the-ball-201601199043

Drug combination effective against chikungunya arthritis in mice

By medicalxpress.com

Combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the disease's earliest stage, according to researchers at Washington University School of Medicine in St. Louis.

The findings could lead to a drug therapy for the painful, debilitating condition for which there currently is no treatment.

"We found that combining these two drugs could abolish the signs of arthritis in mice during the acute phase," said Deborah Lenschow, MD, PhD, an associate professor of medicine and the study's co-senior author, referring to the phase in the first weeks after infection.

The study is published Feb. 1 in Science Translational Medicine.

Until about a decade ago, chikungunya virus, which is transmitted by mosquitoes, mainly was restricted to East Africa and South Asia. But in recent years the virus has spread around the world. The first case originating in the Western Hemisphere was reported in late 2013, and by the end of 2015, the virus had infected an estimated 1.8 million people in the Americas.

Chikungunya infection causes fever and severe joint pain, as well as rash, muscle pain and fatigue. The majority of patients continue to experience joint pain six months after infection, and for some, the arthritis continues for years.

"We were seeing people at our rheumatology clinic whose signs and symptoms really mimicked rheumatoid arthritis but who had been infected with chikungunya," Lenschow said. "This raised the question in our minds, 'Would therapeutics we use to treat rheumatoid arthritis be of any benefit to patients with chikungunya arthritis?'"

To find out, Lenschow, co-senior author Michael Diamond, MD, PhD, and colleagues tested a panel of six rheumatoid arthritis drugs - all approved by the Food and Drug Administration for use in patients - on mice infected with chikungunya virus.

All six drugs work by suppressing the activity of the immune system. Although different in many ways, rheumatoid arthritis and chikungunya arthritis both involve out-of-control immune activity in the joints.

The researchers injected seven groups of mice with the virus and three days later administered one of the six arthritis drugs or a placebo to each group of mice. A week after infection - when the mice's arthritis signs were at their peak - the researchers measured the amount of swelling around the joints as well as the numbers of immune cells and molecules in the affected areas.

Two of the drugs - abatacept and tofacitinib - significantly reduced the swelling and the levels of immune cells and molecules. Importantly, the levels of live virus did not increase in the animals given the immunosuppressive arthritis drugs.

"There was a significant concern that administering any immunosuppressive drug would allow the virus to escape from immune control, leading to worse outcomes in the long term," said Diamond, the Herbert S. Gasser Professor of Medicine. "We've seen that with other viruses, but in this case, none of the drugs seemed to exacerbate viral replication. This raises the possibility that these drugs can be safely investigated in humans."

The treatment was only partially successful at resolving the arthritis, however, which led the researchers to test whether adding a human antibody against chikungunya virus could improve the effectiveness.

As before, the researchers infected mice with the virus and three days later dosed them with the arthritis drug abatacept, the antiviral drug or both. Each drug individually reduced joint swelling a week after infection. But when abatacept and the antiviral drug were used together, the joint swelling and the infectious virus in the animals' joints were eliminated.

"We saw real improvement in the acute phase, but unfortunately, the drug interventions we tried failed to correct the chronic phase," Diamond said.

In humans, the chronic phase of chikungunya arthritis starts three weeks after initial infection and lasts as long as the patient continues to experience joint pain, which can be three or four years. During the chronic phase, infectious virus is no longer detectable in the joints, but viral genetic material persists and may be sufficient to trigger an ongoing immune response, causing the tissue damage that patients perceive as arthritis.

The researchers found a similar pattern in the mice treated with the drug combination: By four weeks after infection, live virus was no longer present in the animals' joints, but viral genetic material remained, suggesting that the drugs had not eliminated the chronic phase of the disease.

It is possible that a treatment that reduces arthritis symptoms in the first weeks after infection could lower the chance that the disease becomes chronic, but no data has yet been published for or against the possibility. Still, any effective treatment, even if short-lived, would be a boon for chikungunya patients, who currently have no proven treatment options. Lenschow has discussed beginning a human study with colleagues in Brazil, but plans are not yet finalized.

"In those first weeks, people are really very sick with a high fever and a lot of pain, so if further studies show that this combination treatment is effective in humans, that will have real benefits for patients," Diamond said. "As for the chronic phase, we're going to continue looking for other treatment strategies."

Source: https://medicalxpress.com/news/2017-02-drug-combination-effective-chikungunya-arthritis.html